MetaCap

Beam Therapeutics (BEAM) vs Vir Biotechnology (VIR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vir Biotechnology (VIR) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 47.7% versus a loss of 5.9%. Over five years, BEAM leads with a -73.4% price change compared with -76.7% for VIR. Beam Therapeutics is the larger company by market cap ($2.16 billion vs $1.56 billion), about 1.4 times the size.

Beam Therapeutics converts more of its revenue into profit, with a net margin of -57.2% versus -638.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAM-5.90%VIR+47.71%
+148%+67%-14%
Nov 21, 20251 yearNov 20, 2026
BEAM-76.70%VIR-74.38%
+72%-11%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAM versus VIR key metrics
MetricBEAMVIR
Share price$20.90$8.39
Market cap$2.16B$1.56B
1-day change-0.19%-5.41%
YTD return-24.60%+39.14%
1-year return-5.90%+47.71%
5-year return-73.44%-76.69%
EPS (TTM)$-0.87$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$139.74M$68.56M
Revenue growth (YoY)+120.01%-7.61%
Net income (latest FY)$-79.99M$-437.99M
Gross margin—99.96%
Operating margin-274.57%-699.18%
Net margin-57.24%-638.87%
52-week high$38.26$14.38
52-week low$20.44$5.45
Distance from 52-week high-45.37%-41.66%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+138.52%+178.67%
Average volume2.04M2.45M
Shares outstanding103.50M186.27M
Employees557367
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VIR has outperformed BEAM by 53.6 percentage points over the past year.
  • Beam Therapeutics is more profitable, keeping -57.2 cents of every revenue dollar as net income versus -638.9 cents for Vir Biotechnology.
  • Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs -7.61%).

About Beam Therapeutics

BEAM stock →

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees

About Vir Biotechnology

VIR stock →

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees

BEAM vs VIR FAQ

Which is bigger, Beam Therapeutics or Vir Biotechnology?

Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.16B compared with $1.56B for Vir Biotechnology (VIR).

Which stock has performed better over the past year, BEAM or VIR?

VIR returned +47.71% over the past 12 months, compared with -5.90% for BEAM (price return, excluding dividends). Past performance does not predict future results.

Are Beam Therapeutics and Vir Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons